The Week in Review: Shanghai Pharma Schedules Hong Kong IPO for May

Shanghai Pharma passed through another regulatory hoop for its $1.8 billion Hong Kong IPO, now scheduled for May; Greek pharma Alapis SA signed a MoU with China’s CSPC Pharma to set up two-way collaboration; Standard Chemical and Pharma of Taiwan announced plans to set up a China JV with Japan’s DIA Pharma; Merck will partner with Sun Pharma of India to produce “innovative branded generics”; Roche completed a $75 million expansion of its Shanghai facility, its headquarters for the Asia Pacific region; Cachet Pharma will spend $9.2 million to upgrade its Beijing drug distribution center; Aoxing Pharma has a very rare China license to produce narcotics, though revenues remain small; and China’s Ministry of Health introduced a three-part ranking for antibiotics to reduce their overuse. More details…. Stock Symbols: (SH: 601607) (Pink Sheets: APSHF) (NYSE: MRK) (BY: 524715) (VS: ROG) (SHE: 002462) (AMEX: AXN) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});